Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
362.5 USD | -1.12% | -1.88% | +2.67% |
Apr. 26 | Declaration of Voting Results of the West Pharmaceutical Services Inc | CI |
Apr. 26 | Bernard Birkett No Longer Have Principal Operating Officer Position of West Pharmaceutical Services, Inc | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.51 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.67% | 26.71B | A- | ||
-4.88% | 183B | C+ | ||
+0.04% | 108B | C | ||
-3.64% | 67.51B | A | ||
+4.06% | 50.67B | B- | ||
+9.06% | 44.7B | B- | ||
+2.41% | 40.95B | B+ | ||
+5.62% | 26.8B | B | ||
+12.66% | 24.62B | A- | ||
-13.28% | 21.38B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WST Stock
- Ratings West Pharmaceutical Services, Inc.